SCHEMBL345582

SCHEMBL345582

CCCCC(NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CTSK P43235 18/20 0.68
CTSS P25774 3/20 0.68
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1350139 1.00 CTSK (0.68) CTSKCTSSMEN1GAAKMT2A
SCHEMBL3448997 1.00 CTSK (0.68) CTSKCTSSMEN1GAAKMT2A
Hydrochloric Acid SCHEMBL6037571 0.98 CTSK (0.66) CTSKCTSSMEN1GAAKMT2A
SCHEMBL14820490 0.95 CTSK (0.62) CTSKCTSSMEN1GAAKMT2A
SCHEMBL18875931 0.95 CTSK (0.62) CTSKCTSSMEN1GAAKMT2A
SCHEMBL3233192 0.95 CTSK (0.62) CTSKCTSSMEN1GAAKMT2A
SCHEMBL29826317 0.94 CTSK (0.69) CTSKCTSS
SCHEMBL7555645 0.94 CTSK (0.60) CTSKCTSS
SCHEMBL5050858 0.94 CTSK (0.60) CTSKCTSS
SCHEMBL7555646 0.94 CTSK (0.60) CTSKCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146032-A1 BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS ALBIREO AB (SE) 2026-05-28 US disclosed
EP-4713321-A1 PROTACS FOR ASK1 PROTEIN DEGRADATION: PREPARATION AND USE THEREOF Council of Scientific and Industrial Research (IN) 2026-03-25 EP disclosed
EP-4707404-A2 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION Ventana Medical Systems, Inc. (US) 2026-03-11 EP disclosed
EP-3492919-B1 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION VENTANA MED SYST INC (US) 2026-01-21 EP disclosed
US-20260001914-A1 MACROCYCLIC PEPTIDES TARGETING KRAS MERCK SHARP & DOHME LLC (US) 2026-01-01 US disclosed
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2025-12-02 US disclosed
US-20250333390-A1 BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS ALBIREO AB (SE) 2025-10-30 US disclosed
US-20250281433-A1 NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME AMTIXBIO CO., LTD. (KR) 2025-09-11 US disclosed
US-12383560-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-12 US disclosed
EP-4347575-B1 BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS ALBIREO AB (SE) 2025-07-23 EP disclosed
WO-1994010151-A1 SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS MERCK & CO., INC. (US) 1994-05-11 WO disclosed
WO-1993020099-A2 CCK AND/OR GASTRIN RECEPTOR LIGANDS FERRING B.V. (NL) 1993-10-14 WO disclosed
EP-0521827-A1 Pharmacological active hydrazin derivatives and process for their preparation CIBA-GEIGY AG (CH) 1993-01-07 EP disclosed
EP-0283365-B1 PEPTIDE DERIVATIVES OF CCK8, THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS THEREOF INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1991-07-10 EP disclosed
US-4985406-A Central nervous system disorders, dopaminergic pathways INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1991-01-15 US disclosed
US-4918105-A Novel compounds with collagenase-inhibiting activity, a process for their preparation and pharmaceutical compositions in which these compounds are present SA LABORATOIRE ROGER BELLON (FR) 1990-04-17 US disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US disclosed
US-4745124-A THIO/ESTER PEPTIDES UNIVERSITY OF MIAMI (US) 1988-05-17 US disclosed
EP-0237264-A2 Process for preparing phosphonyloxyacyl amino acids and derivates thereof E.R. Squibb & Sons, Inc. (US) 1987-09-16 EP disclosed
EP-0036713-B1 ANGIOTENSIN CONVERTING ENZYME INHIBITORS UNIVERSITY OF MIAMI (US) 1984-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333390-A1 BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS SLC10A1, SLC10A2, ABCB11 CTSK 4016/4885CTSS 4416/4885MEN1 4086/4885
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof C5, DPYD, C9 CTSK 2864/4885CTSS 1929/4885MEN1 1464/4885
US-12383560-B2 Compounds and uses thereof VHL, CLN6, TFEB CTSK 2434/4885CTSS 2010/4885MEN1 1366/4885
US-20260001914-A1 MACROCYCLIC PEPTIDES TARGETING KRAS KRAS, NRAS, HRAS CTSK 1467/4885CTSS 1044/4885MEN1 209/4885
US-20250281433-A1 NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME AADAT, AADAC, AHR CTSK 2601/4885CTSS 1691/4885MEN1 4383/4885
US-20260146032-A1 BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS SLC10A2, SLC10A1, SLC5A2 CTSK 3383/4885CTSS 3452/4885MEN1 3097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.